Looking at your number for non primed patients it's 38% for boceprevir at 4 weeks and 69% at 12 weeks. A gradual rise in going undetectable. Whereas VRTX shows about the same numbers at 4 weeks and 12 weeks.
Interestingly, the VRTX numbers in NON RESPONDERS show that similar slow start at 4 weeks to clearing most at 12 weeks.
As an EASL 08 presentation indicates it has been shown many times that at least for SOC treatment, high RVR + EVR correlate with a high SVR. SGP presentation today was supposed to reveal an SVR for the 28 wk arm of B.
If you look at slide 8 from the VRTX EASL webcast for study 107 you'll see that the VRTX drug shows the same low response at 4 weeks vs. 12 weeks in null responders. Too little data to draw conclusions, I just thought it was interesting that the VRTX null responders were showing the same slow response as the SGP non primed naive patients.